

GRO-C

24 May 1978.

Dear Drs. Aronstam and Painter,

Thank you for your letter of 16 May. We agree that if more definitive information could be obtained on the dosages of Factor VIII required that would be helpful.

However, we are not happy about our son, GRO-A being included in an investigation conducted as you describe. We are anxious that the total amount of Factor VIII he receives should be kept to a minimum, particularly to lessen the risk of his developing antibodies to the material.

Over recent holidays we have found that for most bleeds if they are treated promptly, and with sensible behaviour on GRO-A part, 3 240-ml bottles of Hemofil are sufficient to arrest the bleeding and avoid a recurrence.

For a bleed in a 'difficult' place or if treatment is delayed a larger dose is necessary and the risk of a recurrence is considerable. From what we learn from

GRO-A

it seems to us that the dose he usually receives

at the Treloar Haemophilia Centre is quite high and we would not wish him to receive a higher dose except in peculiar circumstances.

As regards GRO-A participation in a study of the effects of a substance which might improve the efficiency of the Factor VIII given, we would have no objection - in fact we are enthusiastic about his doing so.

Yours sincerely,

GRO-A